ADC Therapeutics (ADCT) is a global leader and pioneer in the field of antibody-drug conjugates (ADCs), whose pipeline consists of ADCs in clinical trials for both hematologic and solid tumor cancers. For one, it recently announced the results of a successful trial of a combination of its ZYNLONTA treatment and Rituximab to address relapsed follicular lymphoma (the second most common subtype of non-Hodgkin lymphoma).
Two, there is speculation we could see further M&A with ADCs which could include ADCT, in our opinion. In fact, according to Pfizer’s CEO Albert Bourla, ADCs have become one of the hottest opportunities in oncology, which would explain why it recently acquired Seagen for $34 billion. Even better, Pfizer wants to acquire even more ADC companies.
AbbVie even agreed to acquire Immunogen in a $10.1 billion deal. Plus, late last year, Merck inked a multi-billion-dollar deal with Daiichi to co-develop and commercialize ADCs, as well.